561 related articles for article (PubMed ID: 29183284)
1. Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients.
Qattan A; Intabli H; Alkhayal W; Eltabache C; Tweigieri T; Amer SB
BMC Cancer; 2017 Nov; 17(1):799. PubMed ID: 29183284
[TBL] [Abstract][Full Text] [Related]
2. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
[TBL] [Abstract][Full Text] [Related]
3. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.
McAnena P; Tanriverdi K; Curran C; Gilligan K; Freedman JE; Brown JAL; Kerin MJ
BMC Cancer; 2019 May; 19(1):436. PubMed ID: 31077182
[TBL] [Abstract][Full Text] [Related]
4. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
5. Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
Fkih M'hamed I; Privat M; Ponelle F; Penault-Llorca F; Kenani A; Bignon YJ
Cell Oncol (Dordr); 2015 Dec; 38(6):433-42. PubMed ID: 26392359
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of reference genes for the detection of serum microRNAs by reverse transcription-quantitative polymerase chain reaction in patients with bladder cancer.
Wang L; Liu Y; Du L; Li J; Jiang X; Zheng G; Qu A; Wang H; Wang L; Zhang X; Liu H; Pan H; Yang Y; Wang C
Mol Med Rep; 2015 Jul; 12(1):615-22. PubMed ID: 25738263
[TBL] [Abstract][Full Text] [Related]
7. Aberrant miRNAs expressed in HER-2 negative breast cancers patient.
Braicu C; Raduly L; Morar-Bolba G; Cojocneanu R; Jurj A; Pop LA; Pileczki V; Ciocan C; Moldovan A; Irimie A; Eniu A; Achimas-Cadariu P; Paradiso A; Berindan-Neagoe I
J Exp Clin Cancer Res; 2018 Oct; 37(1):257. PubMed ID: 30342533
[TBL] [Abstract][Full Text] [Related]
8. Global Analysis of miRNA-mRNA Interaction Network in Breast Cancer with Brain Metastasis.
Li Z; Peng Z; Gu S; Zheng J; Feng D; Qin Q; He J
Anticancer Res; 2017 Aug; 37(8):4455-4468. PubMed ID: 28739740
[TBL] [Abstract][Full Text] [Related]
9. Circulating cell-free miRNAs as biomarker for triple-negative breast cancer.
Shin VY; Siu JM; Cheuk I; Ng EK; Kwong A
Br J Cancer; 2015 May; 112(11):1751-9. PubMed ID: 25906045
[TBL] [Abstract][Full Text] [Related]
10. Circulating miRNAs revealed as surrogate molecular signatures for the early detection of breast cancer.
Mishra S; Srivastava AK; Suman S; Kumar V; Shukla Y
Cancer Lett; 2015 Dec; 369(1):67-75. PubMed ID: 26276721
[TBL] [Abstract][Full Text] [Related]
11. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.
Chen X; Xu Y; Liao X; Liao R; Zhang L; Niu K; Li T; Li D; Chen Z; Duan Y; Sun J
Tumour Biol; 2016 Sep; 37(9):11927-11936. PubMed ID: 27075472
[TBL] [Abstract][Full Text] [Related]
12. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
Zhang K; Wang YW; Wang YY; Song Y; Zhu J; Si PC; Ma R
Gene; 2017 Jul; 619():10-20. PubMed ID: 28359916
[TBL] [Abstract][Full Text] [Related]
13. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer.
Zhang Y; Sui J; Shen X; Li C; Yao W; Hong W; Peng H; Pu Y; Yin L; Liang G
Oncol Rep; 2017 Jun; 37(6):3543-3553. PubMed ID: 28498428
[TBL] [Abstract][Full Text] [Related]
14. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study.
Kodahl AR; Lyng MB; Binder H; Cold S; Gravgaard K; Knoop AS; Ditzel HJ
Mol Oncol; 2014 Jul; 8(5):874-83. PubMed ID: 24694649
[TBL] [Abstract][Full Text] [Related]
15. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
[TBL] [Abstract][Full Text] [Related]
16. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection.
Schrauder MG; Strick R; Schulz-Wendtland R; Strissel PL; Kahmann L; Loehberg CR; Lux MP; Jud SM; Hartmann A; Hein A; Bayer CM; Bani MR; Richter S; Adamietz BR; Wenkel E; Rauh C; Beckmann MW; Fasching PA
PLoS One; 2012; 7(1):e29770. PubMed ID: 22242178
[TBL] [Abstract][Full Text] [Related]
17. A nine-miRNA signature as a potential diagnostic marker for breast carcinoma: An integrated study of 1,110 cases.
Xiong DD; Lv J; Wei KL; Feng ZB; Chen JT; Liu KC; Chen G; Luo DZ
Oncol Rep; 2017 Jun; 37(6):3297-3304. PubMed ID: 28440475
[TBL] [Abstract][Full Text] [Related]
18. Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection.
Matamala N; Vargas MT; González-Cámpora R; Miñambres R; Arias JI; Menéndez P; Andrés-León E; Gómez-López G; Yanowsky K; Calvete-Candenas J; Inglada-Pérez L; Martínez-Delgado B; Benítez J
Clin Chem; 2015 Aug; 61(8):1098-106. PubMed ID: 26056355
[TBL] [Abstract][Full Text] [Related]
19. The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs.
Bahrami A; Aledavood A; Anvari K; Hassanian SM; Maftouh M; Yaghobzade A; Salarzaee O; ShahidSales S; Avan A
J Cell Physiol; 2018 Feb; 233(2):774-786. PubMed ID: 28109133
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of microRNAs in triple-negative breast cancer.
Paszek S; Gabło N; Barnaś E; Szybka M; Morawiec J; Kołacińska A; Zawlik I
Ginekol Pol; 2017; 88(10):530-536. PubMed ID: 29192413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
